Accordingly, REV-ERBα is first proposed as a drug target for treating sleep disorders and metabolic syndromes (e.g., dyslipidaemia, hyperglycaemia and obesity). This evidence concerns the gene NR1D1 and obesity due to melanocortin 4 receptor deficiency.